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Abstract 
Cigarette smoking is associated with higher cortisol levels in healthy subjects. In 
schizophrenia this relationship is not clear. There are divergent results on the association 
between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study 
evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30 ± 26.68 years 
old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were 
measured twice, at 08.00 and 09.00 AM, 90-120 min after awakening. The effect of smoking on 
cortisol was evaluated according to current smoking status, the number of cigarettes/day and the 
nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication 
on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and 
chlorpromazine equivalent doses. 
Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, 
and had longer duration of illness than smokers. 
Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking 
status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation 
was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of 
onset or the duration of illness.  
The findings revealed no association between salivary cortisol and smoking, nicotine 
addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between 
salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our 
findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it 
has been shown in healthy individuals. Future studies should investigate a possible 
desensitization of the stress system to smoking. 
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1. Introduction 
Schizophrenia is a severe, heterogeneous chronic mental disorder with diverse clinical 
manifestations, influenced by various genetic risk factors and complex interplay between 
environmental risk factors such as stress exposure and gene–environment interactions. It affects 
about 1% of the population worldwide (Kahn et al., 2015). Patients with schizophrenia have 
dysregulated major system regulating the stress response, the hypothalamic–pituitary–adrenal 
(HPA) axis (Bradley and Dinan, 2010; Brenner et al., 2009; Girshkin et al., 2014; Girshkin et al., 
2016; Walker et al., 2008), manifested in the form of both hyper- and hypofunction (Bradley and 
Dinan, 2010). Schizophrenic patients show altered response to stress compared to control 
subjects (Brenner et al., 2009; Girshkin et al., 2016). The HPA axis abnormalities in 
schizophrenia are indicated by elevated basal cortisol levels (Girshkin et al., 2014; Jakovljevic et 
al., 1998; Muck-Seler et al., 1999), non-suppression of cortisol after dexamethasone suppression 
test (DST) (Hori et al., 2012; Jakovljevic et al., 1998; Muck-Seler et al., 1999), and blunted 
cortisol awakening response (CAR) (Mondelli et al., 2010). Disrupted 24-h diurnal rhythm of 
cortisol secretion (Gallagher et al., 2007) and lower cortisol response to psychological stress 
(Brenner et al., 2009; Gispen-de Wied, 2000) were also reported. However, there are reports 
showing similar basal cortisol concentration between schizophrenia patients and controls 
(Bradley and Dinan, 2010). Some variations in the HPA axis are assumed (Murri et al., 2012) to 
be associated with severity of particular clinical symptoms evaluated by the Positive and 
Negative Syndrome Scale (PANSS) (Kay et al., 1987). However, our previous study did not 
confirm these findings (Pivac et al., 1997). Cortisol was reported to be associated with positive 
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and depressive symptoms, excitement and disorganization in a small sample of first episode 
psychosis (Murri et al., 2012). Although schizophrenia is a neurodevelopmental disorder, the 
neural diathesis-stress model implicates the role of stress and HPA axis, and interaction with 
disturbed dopaminergic pathways, in the etiology of schizophrenia (Pruessner et al., 2016; 
Walker et al., 2008). 
Smoking has been significantly associated with various neuropsychiatric disorders (Dome et 
al., 2010) and psychosocial stress (Slopen et al., 2013). The high incidence of tobacco smoking 
in schizophrenic patients  (Sagud et al., 2009; Winterer, 2010) compared to the general 
population (de Leon and Diaz, 2005; Dome et al., 2010; Manzella et al., 2015) indicates their 
increased susceptibility to nicotine addiction. 
In healthy subjects, elevated cortisol levels are associated with both passive and active 
tobacco smoking (Soldin et al., 2011). Cortisol levels were significantly higher in smokers than 
in non-smokers (Steptoe et al., 2004). These findings were confirmed in the large population 
cohorts of middle-aged (Badrick et al., 2007) and older (Direk et al., 2011) healthy subjects. 
Salivary cortisol levels were higher in current smokers than in non-smokers, but did not differ 
between former smokers and never-smokers (Badrick et al., 2007; Direk et al., 2011). 
The primary hypothesis of this study was that smoking and/or intensity of nicotine addiction 
is significantly associated with salivary cortisol levels in patients with schizophrenia. As the 
effect of smoking on cortisol levels were evaluated in small number of patients with 
schizophrenia (Brenner et al., 2009; Hori et al., 2012; Iancu et al., 2007; Murri et al., 2012), we 
included a fairly large group of inpatients with schizophrenia. Given that smoking affects heart 
rate (Gillum, 1992) and heart rate is regulated by the autonomic nervous system, it was used in 
our study as an indicator of the cardiovascular system function. The second hypothesis of this 
study was that salivary cortisol levels are associated with various clinical symptoms of 
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schizophrenia (Girshkin et al., 2014; Murri et al., 2012) and/or with antipsychotic medication 
(Bradley and Dinan, 2010). Therefore, we assessed the possible associations between salivary 
cortisol, symptoms of schizophrenia, and different antipsychotic medication. 
 
2. Materials and Methods 
2.1. Participants 
The study included 196 inpatients with schizophrenia (51.30 ± 26.68 years old), diagnosed 
using the Structured Clinical Interview for DSM-IV (SCID) (First et al., 1995) and recruited 
from the Psychiatric Hospital Vrapce, Zagreb, Croatia from January 2014 to December 2015. 
Schizophrenic patients were subdivided into 123 smokers (i.e. current smokers) and 73 non-
smokers (i.e. never smokers and former smokers). All patients were Caucasians of Croatian 
origin. Besides the SCID, all patients were assessed for the presence or the severity of particular 
clinical symptoms of schizophrenia using the scores in the total PANSS and PANSS subscales. 
Inclusion criterion was a diagnosis of schizophrenia in subjects older than 18 years. All 
participants were screened for potential medical issues that may influence the HPA axis activity. 
Subjects were excluded if they had diabetes, significant alcohol or substance use, were pregnant, 
in lactation or breast-feeding, received Phenytoin, Ventolin, CRH, ACTH, dexamethasone, 
metyrapone or were treated for arthritis or multiple sclerosis. They were asked to restrain from 
physical activity before the protocol started. Besides nicotine dependence, no other co-morbid 
substance abuse or dependence was present. 
All patients were treated with different antipsychotic medication: olanzapine (5-20 mg/day), 
clozapine (300-800 mg/day), risperidone (2-6 mg/day), fluphenazine (5-15 mg/day), haloperidol 
(4-15 mg/day), promazine (400-500 mg/day), alone or combined with benzodiazepines, i.e. 
diazepam (2-10 mg/day). Mean dose of antipsychotic medication, calculated into chlorpromazine 
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equivalent doses, was 309.5 ± 263.5 mg/day (range 50-1600 mg/day). 
This study was conducted with the approval of the Ethics Committee of the Psychiatric 
Hospital Vrapce, Zagreb, Croatia, and in accordance with the ethical standards established by the 
1975 Declaration of Helsinki. The procedures were discussed with all patients in detail. Patients 
were included in the study after they agreed to participate and provide written informed consent. 
2.2. Assessment of smoking habits/nicotine exposure 
Current smokers were asked to be overnight nicotine abstinent before the sample collection. 
Nicotine dependence was assessed by the medical charts, psychiatric interview and the 
Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al., 1991). Patients were 
subdivided according to the FTND scores into those with mild (less than 5 scores), moderate (5-7 
scores) and severe (more than 7 scores) addiction. 
Patients who regularly smoke 10 or more cigarettes per day (N=123) were asked to smoke 
their own first cigarette with average nicotine amount (containing at least 1 mg of nicotine), in a 
“smoking” protocol, immediately after the first salivary cortisol sampling. Eight days later, a part 
of smokers (N=28) who were included in the previous “smoking” protocol, were asked to refrain 
from smoking their first cigarette, in another “nonsmoking” protocol, between the first and the 
second salivary cortisol sampling. 
2.3. Symptom assessment 
Based on previous factor analyses of PANSS (Citrome et al., 2011; Emsley et al., 2003; Murri 
et al., 2012), symptoms were assessed using the PANSS total and PANSS subscale scores. 
2.4. Cortisol assessment 
Since cortisol levels depend on the time of sampling and cortisol has its peak, i.e. CAR, 30-40 
min after awakening (Girshkin et al., 2016; Stalder et al., 2016), morning salivary cortisol levels 
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( mol/l) were determined in schizophrenic inpatients 90-120 min after awakening. Awakening 
time for all inpatients was between 06.00 – 06.15 AM. To avoid CAR, saliva sampling started at 
08.00 AM after fasting overnight. Patients were asked to refrain from breakfast, coffee, tea, 
smoking, brushing their teeth, taking medication, or doing exercises before collecting salivary 
samples. Subjects were allowed to drink only plain water during the protocol, but not just before 
the salivary cortisol collections. Procedure started by measuring the patients’ heart rate and 
taking the first saliva sample at 08.00 AM using Salimetrics oral swab storage tubes (Salimetrics 
Europe Ltd.) according to manufacturer's instructions (2 minutes under the tongue). Samples 
were immediately refrigerated at 4°C and later stored at -20°C. Second saliva sample (at about 
09.00 AM) was scheduled 45-50 minutes after smoking, or 55-60 minutes after the first salivary 
sample for non-smokers. During this period smokers completed the FTND. Non-smokers rested 
between the first and the second saliva sampling. 
Salivary cortisol levels were measured using Salivary Cortisol Enzyme Immunoassay Kit 
(Salimetrics Europe Ltd.), according to the manufacturer’s instructions. Detection was based on 
a reaction between cortisol conjugated horseradish peroxidase enzyme and tetramethyl-benzidine 
as a substrate. The optical density was read on a standard plate reader at 450 nm. All samples 
were run in duplicates. Samples from an individual patient (sampled at 08.00 and 09.00 AM) 
were analyzed within the same run. Coefficient of variation (CV) was 7.7%, and an inter-assay 
CV was 13.6%. 
Salivary cortisol data were divided according to treatment with typical vs. atypical 
antipsychotics alone or in combination with benzodiazepines, or according to chlorpromazine 
equivalent doses. 
2.5. Heart rate 
Resting heart rate (beats/minute) was measured by a psychiatrist using the palpation 
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method at the wrist (radial artery), by counting the number of beats within a one minute period. 
This procedure was repeated two times: the first heart rate measurement was at 08.00 AM and 
the second measurement was 30 minutes after the first measurement (around 08.30 AM). 
2.6. Data analyses 
All results were evaluated with SigmaStat 3.5 (Jandel Scientific Corp., San Jose, 
California, USA). Normality of the distribution was assessed with the Kolmogorov–Smirnov test. 
Due to non-normal distribution of our data, all analyses were performed using non-parametric 
tests. Age, PANSS scores, age at onset, duration of illness, number of hospitalizations, total 
duration of hospitalizations and chlorpromazine equivalent doses are expressed as median (Q1-
Q3); gender and employment as number (percentages); FTND scores as mean ± SD. Salivary 
cortisol levels ( mol/l), heart rate (bmp) and demographic data between smokers and 
nonsmokers were compared using Mann-Whitney test. Salivary cortisol levels in three different 
groups of subjects subdivided according to the number of cigarettes/day, or according to their 
physical addiction to nicotine, was evaluated using Kruskal Wallis ANOVA on ranks. Wilcoxon 
signed-rank test was used for the comparison of the dependent samples, such as the first and the 
second salivary cortisol concentration and heart rate measured in the same person. A multiple 
regression analysis was used to assess for the influence of gender and age on salivary cortisol 
levels and heart rate. All correlations, of salivary cortisol measured at 08.00 or 09.00 AM, 
absolute change in salivary cortisol and number of cigarettes/day, with 1) FTND scores; 2) 
clinical symptoms of schizophrenia (evaluated using the PANSS total, positive, negative, general 
psychopathology subscales and particular symptom dimensions: selected PANSS positive, 
selected PANSS negative, PANSS excited, PANSS disorganized, PANSS motor, PANSS 
depression, PANSS anxiety and PANSS cognition subscale scores); 3) chlorpromazine 
equivalent doses; 4) demographic variables, were examined using Spearman rank order 
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correlation. 
G*Power 3 Software (Faul et al., 2007) was used for the a priori determination of sample size. 
For Mann-Whitney test (with α = 0.05; power (1 − β) = 0.800; medium effect size (ω = 0.5)) 
required sample size was 184. For Wilcoxon test (matched pairs) (with α = 0.05; power (1 − β) = 
0.800; medium effect size (ω = 0.5)) required sample size was 47. For multiple linear regression, 
(with α = 0.05; power (1 − β) = 0.800; medium effect size (ω = 0.15), and 2 predictors) required 
sample size was 68. Hence the actual sample size of 196 had the needed statistical power (power 
(1 − β) = 0.800) and adequate sample size to detect significant differences among the groups. 
 
3. Results 
3.1. Demographic data in patients with schizophrenia 
Demographic data, as well as PANSS and FTND scores, and chlorpromazine equivalent doses, 
are shown in Table 1. Non-smokers were significantly older, had significantly longer duration of 
illness and received significantly lower doses of antipsychotic medication (calculated as 
chlorpromazine equivalent doses) than smokers. There were no significant differences in the 
distribution of male or female subjects or employment between smokers and nonsmokers. 
Smokers and non-smokers did not differ significantly in the number of hospitalization and total 
duration of hospitalizations (Table 1). 
3.2. Symptoms in smokers and non-smokers 
The total PANSS scores and the PANSS general psychopathology scores were significantly 
higher in non-smokers compared to smokers (Table 1). The PANSS positive and negative scores 
were similar in smokers and non-smokers (Table 1). 
3.3. Salivary cortisol in smokers and non-smokers with schizophrenia 
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Multiple linear regression analysis revealed no significant effect of gender or age on basal 
salivary cortisol levels: (F2,195=0.33, p=0.717, Radj
2=0.000, βage=-0.055, page=0.452, 
βgender=0.030, pgender=0.679 for the first cortisol sample and F2,195=0.26, p=0.769, Radj
2
=0.000, 
βgender=-0.028, pgender=0.700, βage=0.048, page=0.509 for the second cortisol sample). Therefore, in 
all further analyses, cortisol data for men and women were merged. The first or the second 
cortisol measurement did not differ significantly between smokers and non-smokers (Figure 1). 
Both in smokers and in non-smokers, the second cortisol was significantly lower than the first 
cortisol sample (Figure 1). 
To assess whether the number of cigarettes/day affects significantly salivary cortisol levels, 
smokers were subdivided into those smoking 10-20, 21-30 or more than 30 cigarettes per day. 
No significant differences (Kruskal Wallis ANOVA) were found between these groups in the 
first cortisol measurement (H=0.966, df=2, p=0.617). The second salivary cortisol levels were 
similar in smokers smoking 10-20, 21-30 or more than 30 cigarettes per day  (H=3.115, df=2, 
p=0.211). 
In order to evaluate the possible effect of the first cigarette of the day on salivary cortisol 
levels, the difference between the first and the second saliva cortisol sample (absolute change or 
Δ cortisol) was compared in smokers who smoked and smokers who refrained from smoking of 
their first cigarette that day (N=28). Similar change of cortisol was found between those who 
smoked the first cigarette and the same group 8 days later who refrained from smoking of their 
first cigarette (W=30.00, p=0.741, Wilcoxon test). 
To assess (with Kruskal Wallis ANOVA) the possible influence of nicotine dependence on 
second salivary cortisol sample, smokers were subdivided according to the FTND scores. Their 
salivary cortisol levels were similar between 56 patients with mild (9.9 (6.1-16.4) mol/l), 41 
patients with moderate (10.2 (7.8-14.9) mol/l) and 26 patients with severe (10.8 (7.7-16.5) 
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mol/l) physical addiction to nicotine (H=0.181; df=2; p=0.913). The absolute change of 
cortisol between the first and the second salivary sample did not differ significantly when 
smokers were subdivided into those with mild (4.5 (1.3-8.1) mol/l), moderate (5.2 (3.0-8.0) 
mol/l) and severe (3.6 (1.8-6.0) mol/l) physical addiction to nicotine (H=2.379; df=2; 
p=0.304). Spearman rank order correlation revealed a lack of significant correlation between a 
change in salivary cortisol levels and number of smoked cigarettes (r=0.02; p=0.769). No 
significant correlation was detected between a change in salivary cortisol levels and total FTND 
scores (r=0.07; p=0.420). 
3.4. Correlation between salivary cortisol and PANSS scores in smokers and non-smokers 
To examine the association between cortisol and the PANSS scores, Spearman rank order 
correlation was used in patients subdivided into smokers and non-smokers. No significant 
correlations (p0.05) were found between salivary cortisol levels and positive, negative, general 
psychopathology and total PANSS scores in both smokers and non-smokers with schizophrenia 
(data available on request). 
3.5. Correlation between salivary cortisol and PANSS total and selected PANSS subscale scores 
in all patients with schizophrenia 
Spearman rank order correlation revealed a lack of significant correlation between the PANSS 
total or the selected PANSS subscale scores and the first or the second salivary cortisol levels, or 
absolute change (Δ) in salivary cortisol levels in schizophrenic patients (Table 2). No significant 
(p0.05) correlations were found between the cortisol levels (the first and the second salivary 
cortisol sample and a change of salivary cortisol) with the age of onset, duration of illness, 
number of hospitalizations or total duration of hospitalizations in all patients with schizophrenia 
(data available on request). 
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3.6. The association between salivary cortisol concentration and antipsychotic medication 
and/or chlorpromazine equivalent doses in patients with schizophrenia 
Salivary cortisol in patients treated with different antipsychotics alone or in combination with 
benzodiazepines is shown in Table 3 and Supplementary Table 1. The first or the second salivary 
cortisol sample, or a change (Δ) of cortisol did not differ significantly between patients treated 
with different medication (Table 3, Supplementary Table 1). Spearman coefficient of correlation 
revealed that chlorpromazine equivalent doses were not significantly correlated with the first and 
the second salivary cortisol levels, or a change (Δ) of cortisol in patients with schizophrenia 
(Table 3). When patients were divided into smokers and non-smokers, no significant correlation 
was detected between chlorpromazine equivalent doses and the first and the second salivary 
cortisol levels, or a change (Δ) of cortisol (Supplementary Table 2). 
3.7. Heart rate in smokers and non-smokers with schizophrenia 
Multiple linear regression analysis revealed no significant effect of age or gender on the first 
heart rate (F2,195=0.37, p=0.690, Radj
2=0.000, βage=-0.012, page=0.871, βgender=0.062, 
pgender=0.390).  A significant effect of age and a lack of effect of gender was found on the second 
heart rate (F2,194=4.21, p=0.016, Radj
2=0.032, βgender=0.047, pgender=0.511, βage=-0.206, 
page=0.004). Since gender did not significantly affect heart rate, all further analyses for heart rate 
were performed for men and women together. The first heart rate was similar in smokers and 
non-smokers (Figure 2). The second heart rate was significantly higher in smokers compared to 
non-smokers. When the first and the second heart rate were compared in the same person, a 
significantly higher second heart rate was found in smokers after they smoked their first cigarette 
of the day compared to their first measurement. In non-smokers, the second heart rate was 
significantly lower than their first heart rate, and significantly lower compared to the second 
heart rate in smokers (Figure 2). 
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4. Discussion 
The results of the present study showed that 1) patients with schizophrenia who were non-
smokers were older, had longer duration of schizophrenia, had more severe symptoms and were 
treated with lower doses of antipsychotics than smokers; 2) salivary cortisol was similar between 
smokers and non-smokers; and was not associated with smoking the first cigarette of that day, 
the number of cigarettes/day, or the intensity of physical addiction to nicotine; 3) salivary 
cortisol was not correlated with clinical symptoms of schizophrenia; 5) salivary cortisol was not 
associated with chlorpromazine equivalent doses or antipsychotic medication. 
In line with the previous findings (Dickerson et al., 2013; Salokangas et al., 2006) the 
prevalence of tobacco smoking was 64% in this study, and patients smoked around 20 
cigarettes/day. This number might be under-estimated because the inpatients are restricted to 
smoke due to the hospital’s regulations. Non-smokers were older than smokers, had significantly 
higher PANSS total and PANSS general psychopathology scores, longer duration of the illness 
and were treated with lower doses of antipsychotics. These more pronounced symptoms in non-
smokers are presumably due to the longer duration of schizophrenia and treatment with the lower 
doses of antipsychotics compared to smokers. More severe symptoms in non-smokers agree with 
higher negative symptoms and total PANSS scores in Chinese light smokers with schizophrenia 
compared to heavy smokers (Zhang et al., 2014). These results disagree with other data (Aguilar 
et al., 2005; Iancu et al., 2007; Salokangas et al., 2006). The differences between studies might 
be explained by the small number of patients (Iancu et al., 2007), the use of different clinical 
scales (Salokangas et al., 2006), or the subdivision of schizophrenic patients into heavy, mild or 
light smokers (Aguilar et al., 2005; Zhang et al., 2014) compared to smokers and non-smokers in 
the present study. More frequent smoking in schizophrenic patients than in healthy subjects and 
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more severe symptoms in non-smokers might be explained by a form of self-medication, where 
patients smoke since they try to alleviate cognitive and negative symptoms and reduce side 
effects of antipsychotics (Sagud et al., 2008; Winterer, 2010). However, this hypothesis was 
recently criticized, since some predictors for self-medication associated with smoking were not 
confirmed (Manzella et al., 2015). Both regular (Salokangas et al., 2006) and heavy (Zhang et al., 
2014) smoking are general health risks for schizophrenia, and additional health risks for cancer, 
cardiovascular disease and increased mortality. Hence clinicians should focus on the 
interventions for cessation, or at least a reduction of the number of cigarettes smoked per day, as 
integral part of schizophrenia treatment. 
Similarly to previous results (Girshkin et al., 2016; Hori et al., 2012; Murri et al., 2012), and a 
meta-analysis with 2613 schizophrenic patients (Girshkin et al., 2014), in this study salivary 
cortisol levels were not influenced by age or gender in schizophrenic patients. Salivary cortisol 
levels (sampled either at 08.00 or at 09.00 AM) and a change in salivary cortisol were not 
associated with current smoking; the first cigarette smoked that day, the number of cigarettes/day 
and the intensity of physical addiction to nicotine in the present study. These findings might be 
related to the disturbed dopamine metabolism in schizophrenia (Sagud et al., 2009; Walker et al., 
2008; Winterer, 2010). Our data agree with the previous results in patients with schizophrenia 
(Hori et al., 2012; Iancu et al., 2007) or the first episode of psychosis (Mondelli et al., 2010). The 
lack of cortisol response to smoking might be explained with desensitization to smoking, 
possibly due to the dysregulated dopamine metabolism and/or medication use. Namely, cigarette 
smoking usually increases dopamine concentration in mesolimbic system; however 
schizophrenia is characterized by dopaminergic hyperfunction in these regions. Therefore the 
effects of smoking on limbic regions including the HPA axis could be alleviated in schizophrenic 
patients, resulting in a lack of cortisol response (Sagud et al., 2008; Walker et al., 2008; Winterer, 
15 
2010). Our results reveal that smokers and non-smokers with schizophrenia have similar salivary 
cortisol levels, while healthy control smokers have significantly higher salivary cortisol levels 
compared to non-smokers (Badrick et al., 2007; Direk et al., 2011). These findings collectively 
suggest that salivary cortisol is differently affected by smoking in patients with schizophrenia, 
presumably due to the clinically relevant HPA axis dysfunction in schizophrenic patients 
(Bradley and Dinan, 2010), compared to cohorts of general population (Badrick et al., 2007; 
Direk et al., 2011). The possible influence of psychological stress was excluded since the 
identical protocols were used for all patients, suggesting exposure to similar stress levels. A clear 
effect of the diurnal rhythm was confirmed (Hempel et al., 2010) since the second salivary 
cortisol levels were significantly lower in both smokers and non-smokers compared to the first 
measurement at 08:00 AM. 
No correlation was observed between cortisol levels and severity of symptoms in the first 
episode of psychosis patients (Mondelli et al., 2010), or the Brief Psychiatric Rating Scale total 
and subscale scores (Markianos et al., 1999), or positive and negative symptoms of 
schizophrenia (Pivac et al., 1997). In addition, no significant association between 
plasma/salivary cortisol and total PANSS scores (Girshkin et al., 2016; Hori et al., 2012; Strous 
et al., 2009), depressive symptoms (Munro et al., 1984), positive and negative symptoms 
(Girshkin et al., 2016; Hori et al., 2012; Markianos et al., 1999), and general psychopathology 
symptoms (Hori et al., 2012; Markianos et al., 1999) was reported in schizophrenia. Our results 
confirm these data since no significant correlation was detected between the total and the PANSS 
subscale scores and salivary cortisol levels determined either at 08.00 AM or at 09.00 AM or a 
change of cortisol. However, some studies that included rather small number (10-91) of subjects 
and may be underpowered detected positive or negative correlations between plasma or salivary 
cortisol and clinical symptoms of psychosis (Bradley and Dinan, 2010; Murri et al., 2012). These 
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discrepancies might be explained by the differences in diagnoses, rating scales, instruments used 
for assessing clinical symptoms, effect sizes, ethnicities, illness characteristics, illness stage and 
assay methods, plasma vs. salivary cortisol, timing of the cortisol measurement and circadian 
variability of cortisol (Girshkin et al., 2014; Murri et al., 2012).  
In contrast to previous reports (Hatzimanolis et al., 1998; Jakovljevic et al., 2007; Markianos 
et al., 1999; Popovic et al., 2007; Tanaka et al., 2008; Zhang and Zhou, 2005), the present results 
revealed that antipsychotic medication (either neuroleptics or atypical antipsychotics), given as a 
monotherapy or in combination with benzodiazepines, did not affect salivary cortisol levels in 
patients. In addition, the first or the second cortisol measurements or a change in cortisol were 
not significantly associated with chlorpromazine equivalent doses. Smoking also affects 
degradation of most antipsychotics by increasing the activity of the cytochrome P450 isoforms 
and reducing plasma levels of various antipsychotics (Sagud et al., 2008; Winterer, 2010). 
Therefore, the finding of the similar cortisol values in smokers and nonsmokers, and a lack of 
association between salivary cortisol and chlorpromazine equivalent doses or antipsychotic 
medication, might be explained with the inhibitory effect of smoking on antipsychotic doses, 
resulting in reduced antipsychotic plasma levels in smokers and consequently similar cortisol 
values as in nonsmokers. The differences across studies may be explained by differences in 
plasma vs. salivary cortisol measurement or in small number (17-48) of patients in previous 
studies (Hatzimanolis et al., 1998; Jakovljevic et al., 2007; Markianos et al., 1999; Popovic et al., 
2007; Tanaka et al., 2008; Zhang and Zhou, 2005). The discrepancies might also be due to 
differences in the schizophrenia severity, socio-cultural and economic factors, or biological 
heterogeneity (Zhang et al., 2014). In our study patients had similar severity of symptoms (total 
PANSS score range from 61-86), and were ethnically homogeneous and therefore severity of the 
illness and biological heterogeneity might be neglected. However, economic or socio-cultural 
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factors could contribute to these differences. Significant associations between cortisol and 
clinical symptoms of schizophrenia might be lost after clinical improvement and successful 
treatment (Bradley and Dinan, 2010). Since our patients received long-term antipsychotic 
treatment, and their median total PANSS scores (69-79) revealed that they were clinically 
improved, this might explain the lack of association between cortisol, clinical symptoms of 
schizophrenia and antipsychotic medication and/or chlorpromazine equivalent doses. 
As expected (Gillum, 1992), in our study heart rate was higher in smokers compared to non-
smokers. Smokers and non-smokers had similar first heart rate; while the second heart rate, 
measured after the first cigarette smoked that day in smokers, was higher than the first heart rate 
in smokers, and higher than the second heart rate in non-smokers. Since all non-smokers were 
resting between the first and the second heart rate monitoring, their second heart rate was lower 
than the first measurement due to the rest period. In line with the lack of association between 
increased heart rate and elevated salivary cortisol in our study, in patients with chronic 
schizophrenia, heart rate and salivary cortisol did not follow the same pattern of changes 
following stress response (Brenner et al., 2009). 
Limitations of the study: 1) The possible influence of menstrual cycle, use of oral 
contraceptives and hormone replacement therapy (Kudielka et al., 2009) might affect cortisol. 
However our previous study revealed that menstrual status (pre- vs. post-menopausal) did not 
significantly affect plasma cortisol levels (Muck Seler et al., 2004); 2) The influence of genetic 
factors, early stress, social support, social hierarchy and psychological interventions, could also 
affect salivary cortisol and was not determined (Kudielka et al., 2009); 3) Due to the very strict 
protocol, it was not possible to compare the effect of smoking on cortisol between patients with 
schizophrenia and mentally healthy subjects, and/or patients in the first episode or acute phases 
of schizophrenia; 4) since this was a naturalistic study, patients were treated for a long time with 
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different types of antipsychotic medication. Therefore, the data showing a lack of association 
between salivary cortisol and antipsychotic medication and/or chlorpromazine equivalent doses 
are preliminary. 
The strengths of the study were: 1) this study included the largest sample of inpatients with 
schizophrenia, a homogenous population of the same ethnic origin, recruited from the same 
center, allowing adequate statistical power and sample size, calculated “a priori” as suggested 
(Kudielka et al., 2009); 2) basal salivary cortisol was evaluated in a hospital setting in a closely 
followed protocol (Stalder et al., 2016); 3) smoking behavior was evaluated in details. Therefore, 
these data might be used for the future meta-analyses. 
 
5. Conclusions 
The results of the present study revealed that salivary cortisol was not influenced by smoking, 
nicotine addiction intensity or clinical symptoms of schizophrenia. Our preliminary data showed 
no correlation between salivary cortisol and chlorpromazine equivalent doses. The data suggest 
that patients with schizophrenia differ from the general population in the HPA axis’ responses to 
smoking and nicotine addiction. The differences might be explained by the HPA axis 
dysfunction in patients with schizophrenia (Bradley and Dinan, 2010), and a disrupted cortisol 
stress reactivity (Girshkin et al., 2016), presumably related to frequent hospitalizations, long 
duration of illness and long term antipsychotic treatment, possible lack of social support or 
particular genetic factors (Kudielka et al., 2009).  
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Figure 1. The first (Cortisol 1) and the second (Cortisol 2) salivary cortisol sample in 
schizophrenic smokers and non-smokers. *(W=-4583.00; p<0.001, Wilcoxon test) vs. the first 
cortisol sample in smokers; **(W=-1669.00; p<0.001, Wilcoxon test) between smokers and 
nonsmokers in the first cortisol sample; (U=4067.00; p=0.272, Mann Whitney test) between 
smokers and nonsmokers in the first cortisol sample; (U=3951.00;  p=0.161; Mann Whitney test) 
between smokers and nonsmokers in the second cortisol sample. 
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Figure 2. The first (HR1) and the second (HR2) heart rate in schizophrenic smokers and non-
smokers. *(W=9641.00, p<0.001, Wilcoxon test) vs. the first heart rate sample in smokers; 
**(W=-1343.00, p=0.003, Wilcoxon test) vs. the first heart rate in non-smokers; 
#
(U=7227.00; 
p<0.001, Mann-Whitney test) vs. the second heart rate in smokers;  (U=701.50, p=0.754, Mann-
Whitney test) for the first heart rate between smokers and non-smokers. 
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Table 1. Demographic data, PANSS, FTND and VAS scores for patients with schizophrenia 
subdivided according to their smoking status 
 Smokers Non-smokers Statistical analysis 
Smoking status N (%) 123 (62.8) 73 (37.2)  
Age (years) 49.0 
(39.0-54.0) 
56.0* 
(45.0-62.0) 
U=2793.5; 
p=0.001; MW test 
Gender Females 76 (38.8) 53 (27.0)  
2=1.925; df=1; 
p=0.165; 2  test 
Males 47 (24.0) 20 (10.2) 
Employment Yes 15 (7.6) 7 (3.6) 2=0.105; df=1; 
p=0.745; 2  test 
No 108 (55.1) 66 (33.7) 
Number of cigarettes 22.6±4.9 0  
Age at onset (years)  30.0 
(25.0-36.0) 
32.0 
(30.0-36.0) 
U=3973.0; 
p=0.207; MW test 
Duration of illness (years) 15.5 
(7.0-24.0) 
20.0* 
(11.5-29.0) 
U=3298.0; 
p=0.002; MW test 
Number of hospitalizations 4.0 
(2.0-5.0) 
4.0 
(3.0-5.0) 
U=4047.0; 
p=0.281; MW test 
Total duration of 
hospitalizations (months) 
6.0 
(3.0-9.0) 
6.0 
(4.0-12.0) 
U=3878.0; 
p=0.130; MW test 
Chlorpromazine equivalent 
doses 
200 
 (200-400) 
200* 
 (100-300) 
U=3011.0; 
p=0.0001; MW 
test 
PANSS total scores 69.0 (61.3-79.8) 79.0 (70.0-86.3)* U=2950.0; 
p=0.001; MW test 
PANSS positive scores 16.0 (13.0-18.8) 17.0 (14.0-19.0) U=3811.0; 
p=0.076; MW test 
PANSS negative scores 20.0 (17.0-22.0) 21.0 (18.0-24.0) U=3750.5; 
p=0.053; MW test 
28 
PANSS general scores 34.0 (29.0-41.0) 41.0 (37.0-46.0)* U=2677.0; 
p=0.001; MW test 
FTND total scores 4.8±2.2 0  
PANSS: Positive and Negative Syndrome Scale; FTND: Fagerstrom Test for Nicotine 
Dependence; age, PANSS scores, age at onset, duration of illness, number of hospitalizations, 
total duration of hospitalizations and chlorpromazine equivalent doses are expressed as median 
(Q1-Q3); gender and employment as number (percentages); FTND scores as mean ± SD; MW: 
Mann Whitney test; 2 test=chi square test. *= significant 
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Table 2. The lack of correlation between the PANSS total or the selected PANSS subscale 
scores and the first (salivary cortisol 1), the second (salivary cortisol 2) salivary cortisol 
concentration, or the absolute difference between the first and the second salivary cortisol 
concentration (Δ cortisol) in 196 patients with schizophrenia 
PANSS scale and subscales 
(scores)  
Cortisol 1 
( mol/l) 
Cortisol 2 
mol/l) 
Δ cortisol 
mol/l) 
PANSS total   
Correlation Coefficient -0.05 -0.01 -0.05 
p Value 0.523 0.875 0.483 
PANSS Positive total   
Correlation Coefficient 0.06 0.04 0.02 
p Value 0.378 0.537 0.813 
PANSS Negative total   
Correlation Coefficient -0.08 -0.02 -0.02 
p Value 0.269 0.748 0.818 
PANSS General psychopathology total       
Correlation Coefficient -0.07 -0.03 -0.08 
p Value 0.325 0.641 0.245 
PANSS delusions (P1)  
Correlation Coefficient 0.01 -0.12 0.02 
p Value 0.898 0.138 0.759 
PANSS hallucinatory behavior (P3)    
Correlation Coefficient 0.01 0.02 0.00 
p Value 0.918 0.823 1.000 
Selected PANSS positive (P1+P3+P5+P6+G9)  
Correlation Coefficient 0.01 -0.05 -0.05 
p Value 0.862 0.445 0.496 
30 
Selected PANSS negative 
(N4+N2+N3+G16+N6+N1+G13) 
 
Correlation Coefficient -0.08 -0.03 0.00 
p Value 0.289 0.713 0.996 
Selected PANSS positive 
(P1+G9+P3+P6+P5+G12+G15) 
 
Correlation Coefficient -0.02 -0.05 -0.08 
p Value 0.800 0.457 0.262 
PANSS disorganized (G10+G11+N5+P2+N7)    
Correlation Coefficient -0.04 0.01 -0.04 
p Value 0.565 0.913 0.562 
PANSS excited (P7+G14+P4+G8)  
Correlation Coefficient -0.01 0.06 -0.03 
p Value 0.866 0.377 0.683 
PANSS motor (G5+G7)  
Correlation Coefficient -0.10 -0.03 -0.09 
p Value 0.150 0.639 0.188 
PANSS depression (G6+G3)  
Correlation Coefficient 0.04 -0.00 -0.00 
p Value 0.587 0.983 0.951 
PANSS anxiety (G1+G2+G4)  
Correlation Coefficient -0.04 -0.03 0.00 
p Value 0.553 0.695 0.986 
PANSS cognition 
(P2+N5+N7+G5+G10+G11+G12+G13+G1) 
   
Correlation Coefficient -0.06 -0.01 -0.06 
p Value 0.400 0.934 0.429 
Correlation between the PANSS scores and salivary cortisol was evaluated using the Spearman 
rank order correlation; PANSS: Positive and Negative Syndrome Scale 
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Table 3. The first, the second and a change (Δ) of salivary cortisol concentration in 
schizophrenic patients divided according to their pharmacotherapy 
  
N 
Cortisol 1 
( mol/l) 
Cortisol 2 
( mol/l) 
Δ cortisol 
( mol/l) 
Antipsychotics Atypical 171 15.9 
(9.3-19.7) 
11.2 
(7.0-17.0) 
4.9 
(2.1-7.7) 
 Typical 25 14.0 
(9.3-16.3) 
9.5 
(7.4-14.1) 
5.0 
(1.0-7.6) 
 MW test  U=2447.00 
p=0.243 
U=2475.00 
p=0.203 
U=2249.00 
p=0.675 
Antipsychotics  +benzodiazepines 10 14.5 
(5.7-18.7) 
9.7 
(4.5-19.3) 
2.5 
(0.9-7.6) 
- benzodiazepines 186 15.2 
(9.4-19.6) 
10.9 
(7.2-16.1) 
4.9 
(2.1-7.7) 
 MW test  U=1087.00 
p=0.370 
U=999.00 
p=0.695 
U=1112.00 
p=0.299 
Chlorpromazine 
equivalent 
doses 
(mg/day) 
Spearman 
Correlation 
Coefficient 
196 r=0.087; 
p=0.225 
r=0.056; 
p=0.431 
r=-0.004; 
p=0.578 
MW test: Mann Whitney test; Salivary cortisol concentration is expressed as median (Q1-Q3), 
N=number of patients. 
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Supplementary Table 1. The first (salivary cortisol 1), the second (salivary cortisol 2) salivary 
cortisol concentration, or the absolute difference between the first and the second salivary 
cortisol concentration (Δ cortisol) in schizophrenic patients divided according to monotherapy 
with antipsychotic medication 
Drug   N 
Cortisol 1 
( mol/l) 
Cortisol 2 
( mol/l) 
Δ cortisol 
( mol/l) 
Olanzapine 
Yes 116 
14.2 
(8.5-19.5) 
10.9 
(6.2-16.1) 
4.7 
(2.1-7.9) 
No 80 
15.8 
(10.7-19.6) 
10.9 
(7.8-16.2) 
4.9 
(1.7-7.5) 
 MW test  
U=4280.00 
p=0.357 
U=4375.00 
p=0.498 
U=4833.00 
p=0.622 
Risperidone 
Yes 57 
16.2 
(11.2-20.1) 
13.1 
(7.8-17.6) 
4.9 
(1.8-7.6) 
No 139 
14.1 
(9.0-19.4) 
10.2 
(6.7-15.4) 
4.7 
(2.0-7.7) 
 MW test  
U=3386.00 
p=0.111 
U=3439.00 
p=0.148 
U=3374.00 
p=0.823 
Clozapine 
Yes 9 
16.2 
(13.8-20.5) 
13.3 
(11.3-17.6) 
3.5 
(2.4-5.1) 
No 187 
14.7 
(9.3-19.5) 
10.8 
(6.8-16.1) 
4.9 
(2.0-7.7) 
 MW test  
U=726.00 
p=0.489 
U=576.00 
p=0.111 
U=999.00 
p=0.345 
Fluphenazine 
Yes 17 
14.0 
(10.4-16.1) 
9.5 
(7.1-12.7) 
3.8 
(1.0-6.7) 
No 179 
15.8 
(9.3-19.7) 
11.1 
(7.2-16.5) 
4.9 
(2.1-7.8) 
 MW test  
U=1783.00 
p=0.243 
U=1796.00 
p=0.220 
U=1783.00 
p=0.243 
Haloperidol Yes 6 
13.9 
(9.1-20.3) 
9.3 
(8.8-14.1) 
6.3 
(0.6-10.5) 
33 
No 190 
15.2 
(9.4-19.5) 
10.9 
(7.2-16.2) 
4.8 
(2.0-7.6) 
 MW test  
U=589.00, 
p=0.892 
U=648.00 
p=0.571 
U=530.00 
p=0.773 
Promazine 
Yes 2 
13.0 
(9.4-16.5) 
12.5 
(7.9-17.1) 
8.2 
(7.7-8.6) 
No 194 
14.9 
(9.3-19.6) 
10.9 
(7.2-16.1) 
4.8 
(2.0-7.6) 
 MW test  
U=223.00 
p=0.721 
U=179.00 
p=0.856 
U=84.00 
p=0.170 
Salivary cortisol concentration is expressed as median (Q1-Q3), N=number of patients, data 
analyzed by Mann-Whitney test. 
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Supplementary Table 2: Lack of correlation between chlorpromazine equivalent doses and the 
first (salivary cortisol 1), the second (salivary cortisol 2) salivary cortisol, or the absolute 
difference (Δ cortisol) between the first and the second salivary cortisol levels in 123 smokers 
and 73 non-smokers with schizophrenia 
Chlorpromazine equivalent doses 
(mg/day) 
Cortisol 1 
( mol/l) 
Cortisol 2 
( mol/l) 
Δ cortisol 
( mol/l) 
Smokers   
Correlation Coefficient r=0.088 r=0.127 r=-0.025 
p Value 0.329 0.160 0.786 
Non-smokers   
Correlation Coefficient r=0.196 r=0.068 r=-0.023 
p Value 0.096 0.568 0.846 
Correlation between cortisol chlorpromazine equivalent doses and salivary cortisol was 
evaluated using the Spearman Correlation Coefficient. 
 
